Holen Sie sich die Stockscreener-App
21.98
6.79%
-1.60
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$23.58
Offen:
$21.5
24-Stunden-Volumen:
3.06M
Relative Volume:
2.24
Marktkapitalisierung:
$1.91B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-4.8308
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
-4.06%
1M Leistung:
+12.95%
6M Leistung:
+152.93%
1J Leistung:
+178.93%
1-Tages-Spanne:
$21.00
$22.90
1-Wochen-Bereich:
$21.00
$23.69
52-Wochen-Spanne:
$5.12
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.98 | 1.91B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Travere Therapeutics price target raised to $30 from $24 at TD Cowen - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2024 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Full Year 2024 Earnings: EPS Misses Expectations - Yahoo Finance
Travere Therapeutics’ Earnings Call Reveals Growth and Challenges - TipRanks
US FDA approves Mirum Pharma's genetic disorder drug -February 21, 2025 at 12:07 pm EST - Marketscreener.com
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
Travere therapeutics chief medical officer sells $60k in stock - MSN
Travere Therapeutics Inc (TVTX) Q4 2024 Earnings Call Highlights: Strong Phil Spari Sales and ... - Yahoo Finance
Travere Therapeutics Posts Strong 2024 Financial Results - TipRanks
Earnings call transcript: Travere Therapeutics Q4 2024 sees earnings beat but stock drops - Investing.com
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key Metrics - Yahoo Finance
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Travere: Q4 Earnings Snapshot - Danbury News Times
Travere: Q4 Earnings Snapshot -February 20, 2025 at 04:27 pm EST - Marketscreener.com
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
Earnings: Travere Q4 Revenue Surges 84% as FILSPARI Sales Hit $132M in First Year | TVTX Stock News - StockTitan
What To Expect From Travere Therapeutics Inc (TVTX) Q4 2024 Earnings - Yahoo Finance
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - MSN
Entropy Technologies LP Makes New $214,000 Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
TVTX Stock Soars to 52-Week High, Reaching $20.36 - MSN
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics - Yahoo Finance
Travere Therapeutics (TVTX) Projected to Post Earnings on Thursday - MarketBeat
Leerink Partnrs Has Strong Forecast for TVTX FY2026 Earnings - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Given New $45.00 Price Target at Evercore ISI - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Peter Heerma Sells 3,074 Shares - MarketBeat
Travere therapeutics director Roy Baynes sells $220,000 in stock - MSN
Sandra Calvin Sells 54,244 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
William E. Rote Sells 5,200 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Eric M. Dube Sells 11,375 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock - MarketBeat
Scotiabank Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00 at Canaccord Genuity Group - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Sells $220,000.00 in Stock - MarketBeat
Travere therapeutics officer sells shares worth over $1.35 million - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Travere Therapeutics (TVTX): Among The Small–Cap Stocks Insiders Are Selling Recently - Insider Monkey
10 Small–Cap Stocks Insiders Are Selling Recently - Insider Monkey
Travere Therapeutics price target raised to $47 from $45 at Guggenheim - TipRanks
Industry Analysts Just Made A Substantial Upgrade To Their Travere Therapeutics, Inc. (NASDAQ:TVTX) Revenue Forecasts - Simply Wall St
Travere Therapeutics (NASDAQ:TVTX) Sets New 1-Year HighTime to Buy? - MarketBeat
Canaccord raises Travere Therapeutics target to $45; Keeps Buy - MSN
Travere therapeutics SVP Elizabeth Reed sells $188,240 in stock By Investing.com - Investing.com Australia
Earnings Alert: Travere Therapeutics Sets Critical Q4 & FY24 Results RevealKey Details Inside - StockTitan
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug - MSN
Travere therapeutics CCO Heerma sells shares worth $137,275 - MSN
Travere Therapeutics price target raised to $32 from $27 at Scotiabank - Yahoo Finance
Travere therapeutics officer sells shares worth over $1.35 million By Investing.com - Investing.com South Africa
Travere therapeutics CEO Eric M. Dube sells $273,455 in stock - MSN
Travere therapeutics CCO Heerma sells shares worth $137,275 By Investing.com - Investing.com Nigeria
Travere therapeutics executive sells shares worth $122,356 By Investing.com - Investing.com South Africa
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Travere Therapeutics Inc-Aktie (TVTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| REED ELIZABETH E | SVP, GC & CORPORATE SECRETARY |
Feb 12 '25 |
Sale |
23.53 |
8,000 |
188,240 |
89,482 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER |
Feb 11 '25 |
Option Exercise |
16.63 |
45,000 |
748,200 |
78,654 |
| Calvin Sandra | SVP, CHIEF ACCOUNTING OFFICER |
Feb 11 '25 |
Sale |
25.00 |
54,244 |
1,356,100 |
54,410 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
Feb 11 '25 |
Sale |
25.00 |
3,074 |
76,850 |
127,634 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
Feb 12 '25 |
Sale |
23.53 |
2,568 |
60,426 |
125,066 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
Feb 11 '25 |
Sale |
24.04 |
11,375 |
273,455 |
419,173 |
| Inrig Jula | CHIEF MEDICAL OFFICER |
Feb 12 '25 |
Sale |
23.53 |
2,568 |
60,426 |
89,602 |
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):